The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
SERUM PROSTATE SPECIFIC ANTIGEN IS A STRONG PREDICTOR OF FUTURE PROSTATE GROWTH IN MEN WITH BENIGN PROSTATIC HYPERPLASIA
Abstract
PURPOSE: We analyze patterns of prostate growth in men diagnosed with benign prostatic hyperplasia (BPH) and treated with placebo during 4 years, and determine which baseline parameters were the strongest predictors of growth. MATERIALS AND METHODS: A total of 3,040 men were enrolled in the 4-year randomized, placebo controlled Proscar Long-Term Efficacy and Safety study. Of these men a subgroup of 10% underwent pelvic magnetic resonance imaging prostate volume measurement at baseline and yearly thereafter. Absolute and percent volume changes during 4 years were calculated in the 164 placebo treated men in the subgroup. The ability of age, baseline prostate volume and prostate specific antigen (PSA) to predict prostate growth in placebo treated patients was assessed by multiple linear regression analyses, receiver operator characteristics curves, and evaluations of growth stratified by tertiles of baseline serum PSA and decades of life. RESULTS: In placebo treated patients a steady increase in mean plus or minus standard deviation prostate volume from year to year was noted (2.5+/-6.1, 4.9+/-6.8, 6.4+/-8.5 and 7.2+/-8.8 ml. at years 1, 2, 3 and 4, respectively). Mean volume changes at 4 years ranged from -9 to +30 ml. Mean percent change from baseline ranged from 12.5% to 16.6% for men 50 to 59 years old to those 70 to 79 years old. Baseline serum PSA was a strong predictor of growth with 7.4% to 22.0% change at 4 years from the lowest to highest PSA tertiles. Annualized growth rates from baseline were 0.7 ml. per year for PSA 0.2 to 1.3, 2.1 for PSA 1.4 to 3.2 and 3.3 for PSA 3.3 to 9.9 ng./ml. Multiple linear regression analysis showed that serum PSA was a stronger predictor of prostate growth than age or baseline prostate volume. All but 1 man with baseline serum PSA greater than 2.0 ng./ml. had prostate growth during 4 years, and 32.6% of men with serum PSA less than 2.0 exhibited a decrease in volume. CONCLUSIONS: Serum PSA is a stronger predictor of growth of the prostate in placebo treated patients than age or baseline prostate volume. Since prostate volume is a risk factor for acute urinary retention and the need for BPH related surgery, the ability of PSA to predict prostate growth may be an important factor when considering individual treatment options for BPH. Such use of PSA represents a shift in paradigm away from focusing solely on symptoms of BPH toward a more comprehensive approach with consideration of predicting and preventing risk factors of BPH related outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The American Urological Association Symptom Index for Benign Prostatic Hyperplasia
Barry, M. J., Fowler, F. J., O’Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. K., & The Measurement Committee of the American Urological Association (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)36966-5 · Cited by 3,436
Self-citationThe American Urological Association Symptom Index for Benign Prostatic Hyperplasia
Barry, M. J., Fowler, F. J., O'leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. K., & Measurement Committee of the American Urological Association (2017) · Journal of Urology · doi:10.1016/j.juro.2016.10.071 · Cited by 1,940
Self-citationMcConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802263380901 · Cited by 1,120
Self-citationThe Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia
Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., Haakenson, C., Machi, M., Narayan, P., & Padley, R. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608223350801 · Cited by 792
Natural History of Prostatism: Risk Factors for Acute Urinary Retention
Jacobsen, S. J., Jacobson, D. J., Girman, C. J., Roberts, R. O., Rhodes, T., Guess, H. A., & Lieber, M. M. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64508-7 · Cited by 672
Boyle, P., Lawrence Gould, A., & Roehrborn, C. G. (1996) · Urology · doi:10.1016/s0090-4295(96)00353-6 · Cited by 469
Self-citationBarry, M. J., Cockett, A. T. K., Holtgrewe, H. L., McConnell, J. D., Sihelnik, S. A., & Winfield, H. N. (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)35482-4 · Cited by 400
Self-citationBarry, M. J., Fowler, F. J., Mulley, A. G., Henderson, J. V., & Wennberg, J. E. (1995) · Medical Care · doi:10.1097/00005650-199508000-00003 · Cited by 383
Roehrborn, C. G., McConnell, J. D., Lieber, M., Kaplan, S., Geller, J., Malek, G. H., Castellanos, R., Coffield, S., Saltzman, B., Resnick, M., et al. (1999) · Urology · doi:10.1016/s0090-4295(98)00654-2 · Cited by 333
Self-citationBenign Prostatic Hyperplasia: Diagnosis and Treatment
(1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb06659.x · Cited by 309
Cited by
McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Dixon, C. M., Kusek, J. W., Lepor, H., McVary, K. T., Nyberg, L. M., Clarke, H. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030656 · Cited by 2,043
Self-citationGratzke, C., Bachmann, A., Descazeaud, A., Drake, M. J., Madersbacher, S., Mamoulakis, C., Oelke, M., Tikkinen, K. A. O., & Gravas, S. (2015) · European Urology · doi:10.1016/j.eururo.2014.12.038 · Cited by 1,010
AUA PRACTICE GUIDELINES COMMITTEE (2003) · Journal of Urology · doi:10.1097/01.ju.0000078083.38675.79 · Cited by 844
Roehrborn, C. G., Boyle, P., Nickel, J. C., Hoefner, K., & Andriole, G. (2002) · Urology · doi:10.1016/s0090-4295(02)01905-2 · Cited by 729
Self-citationBenign prostatic hyperplasia: an overview
Ziada, A., Rosenblum, M., & Crawford, E. D. (1999) · Urology · doi:10.1016/s0090-4295(98)00532-9 · Cited by 431
Metadata
- Authors
- ROEHRBORN, C. G., McCONNELL, J., BONILLA, J., ROSENBLATT, S., HUDSON, P. B., MALEK, G. H., SCHELLHAMMER, P. F., BRUSKEWITZ, R., MATSUMOTO, A. M., HARRISON, L. H., FUSELIER, H. A., WALSH, P., ROY, J., ANDRIOLE, G., RESNICK, M., WALDSTREICHER, J., & STUDY, F. T. P. L.-T. E. A. S.
- Venue
- Journal of Urology
- Published
- 2000-01
- Volume
- 163
- Issue
- 1
- Pages
- 13-20
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2010616721
- Cited by
- 265
- References
- 13
- FWCI
- 17.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SERUM PROSTATE SPECIFIC ANTIGEN IS A STRONG PREDICTOR OF FUTURE PROSTATE GROWTH IN MEN WITH BENIGN PROSTATIC HYPERPLASIA. https://app.cochat.ai/papers/10.1016/s0022-5347(05)67962-1
- The paper
- ROEHRBORN, C. G., McCONNELL, J., BONILLA, J., ROSENBLATT, S., HUDSON, P. B., MALEK, G. H., SCHELLHAMMER, P. F., BRUSKEWITZ, R., MATSUMOTO, A. M., HARRISON, L. H., FUSELIER, H. A., WALSH, P., ROY, J., ANDRIOLE, G., RESNICK, M., WALDSTREICHER, J., & STUDY, F. T. P. L.-T. E. A. S. (2000). SERUM PROSTATE SPECIFIC ANTIGEN IS A STRONG PREDICTOR OF FUTURE PROSTATE GROWTH IN MEN WITH BENIGN PROSTATIC HYPERPLASIA. Journal of Urology. https://doi.org/10.1016/s0022-5347(05)67962-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.